Rafferty Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Rafferty Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-35,586	Closed	-$640K	–	1069
2020 Q2	$640K	Buy	35,586 +25,185	+242%	+$350K	0.01%	652
2020 Q1	$74K	Sell	10,401 -78,028	-88%	-$974K	﹤0.01%	568
2019 Q4	$2.11M	Sell	88,429 -80,005	-47%	-$2.21M	0.03%	369
2019 Q3	$4.52M	Sell	168,434 -23,569	-12%	-$662K	0.07%	164
2019 Q2	$5.21M	Buy	192,003 +37,696	+24%	+$1.18M	0.09%	152
2019 Q1	$5.35M	Buy	+154,307	New	+$4.45M	0.09%	125

Rafferty Asset Management's PTLA Position: Q3 2020 in Review

Rafferty Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 35,586 shares — an estimated $640K sold.

Rafferty Asset Management first reported a position in PTLA in Q1 2019 and held it in 6 quarters. The position peaked at $5.35M in Q1 2019. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

Rafferty Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Rafferty Asset Management sold 35,586 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $640K.
Rafferty Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and held it in 6 quarters.
Rafferty Asset Management's Portola Pharmaceuticals, Inc. position peaked at $5.35M in Q1 2019.
0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Rafferty Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.